Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mu Sun

Showing results (51-60 of 349) with videos related to

Pageof 35
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 17, 2014
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21Sung Hee Lim, Ji Yun Lee, Jong-Mu Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 24, 2018
Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung CancerJang Ho Cho, Jong-Mu Sun, Se-Hoon Lee, et al.
Expert Review of Molecular Diagnostics|August 26, 2017
An update on biomarkers for kinase inhibitor response in non-small-cell lung cancerBo Mi Ku, Jong-Mu Sun, Se-Hoon Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|June 12, 2020
Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study)Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, et al.
Expert Opinion on Biological Therapy|January 23, 2016
Pembrolizumab for the treatment of non-small cell lung cancerSung Hee Lim, Jong-Mu Sun, Se-Hoon Lee, et al.
Clinical Nuclear Medicine|December 6, 2018
Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: FDG Uptake and Risk StratificationSeung Hwan Moon, Jong-Mu Sun, Jin Seok Ahn, et al.
Journal of Cachexia, Sarcopenia and Muscle|April 13, 2024
Prognostic impact of muscle mass loss in elderly patients with oesophageal cancer receiving neoadjuvant chemoradiation therapyJeong Yun Jang, Dongryul Oh, Jae Myoung Noh, et al.
Translational Lung Cancer Research|October 19, 2023
Real-world clinical evidence of lazertinib use in acquired <i>EGFR</i> T790M mutated non-small cell lung cancerSehhoon Park, Hyun Ae Jung, Se-Hoon Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|September 16, 2015
Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIsSu Jin Lee, Jong-Mu Sun, Se Hoon Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 5, 2017
Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung CancerSong Ee Park, Se Hoon Lee, Jin Seok Ahn, et al.
Pageof 35

Showing results (51-60 of 349) with videos related to

Sort By:
Pageof 35
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 17, 2014
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21Sung Hee Lim, Ji Yun Lee, Jong-Mu Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 24, 2018
Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung CancerJang Ho Cho, Jong-Mu Sun, Se-Hoon Lee, et al.
Expert Review of Molecular Diagnostics|August 26, 2017
An update on biomarkers for kinase inhibitor response in non-small-cell lung cancerBo Mi Ku, Jong-Mu Sun, Se-Hoon Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|June 12, 2020
Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study)Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, et al.
Expert Opinion on Biological Therapy|January 23, 2016
Pembrolizumab for the treatment of non-small cell lung cancerSung Hee Lim, Jong-Mu Sun, Se-Hoon Lee, et al.
Clinical Nuclear Medicine|December 6, 2018
Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: FDG Uptake and Risk StratificationSeung Hwan Moon, Jong-Mu Sun, Jin Seok Ahn, et al.
Journal of Cachexia, Sarcopenia and Muscle|April 13, 2024
Prognostic impact of muscle mass loss in elderly patients with oesophageal cancer receiving neoadjuvant chemoradiation therapyJeong Yun Jang, Dongryul Oh, Jae Myoung Noh, et al.
Translational Lung Cancer Research|October 19, 2023
Real-world clinical evidence of lazertinib use in acquired <i>EGFR</i> T790M mutated non-small cell lung cancerSehhoon Park, Hyun Ae Jung, Se-Hoon Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|September 16, 2015
Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIsSu Jin Lee, Jong-Mu Sun, Se Hoon Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 5, 2017
Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung CancerSong Ee Park, Se Hoon Lee, Jin Seok Ahn, et al.
Pageof 35